$CMPX
Compass Therapeutics Inc. Stock $cmpx

$cmpx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000117184323002868 Filed on May 04, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.114M	$3.073M	$2.767M
YoY Change	-0.35%	11.06%	5.01%
% of Gross Profit
Research & Development	$10.22M	$6.638M	$4.415M
YoY Change	74.39%	50.35%	-6.14%
% of Gross Profit
Depreciation & Amortization	$180.0K	$200.0K	$200.0K
YoY Change	-18.18%	0.0%	0.0%
% of Gross Profit
Operating Expenses	$13.34M	$9.711M	$7.182M
YoY Change	48.4%	35.21%	-2.14%
Operating Profit	-$13.34M	-$9.711M	-$7.182M
YoY Change	48.4%	35.21%	-2.14%
Interest Expense	$2.059M	$1.874M	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$2.059M	$1.874M	$20.00K
YoY Change	317.65%	9270.0%	-124.1%
Pretax Income	-$11.28M	-$7.837M	-$7.162M
YoY Change	32.78%	9.42%	-3.5%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$11.28M	-$7.837M	-$7.162M
YoY Change	32.78%	9.42%	-3.5%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.09	-$0.06	-$0.07
Diluted Earnings Per Share	-$0.09	-$0.06	-$71.01K
COMMON SHARES
Basic Shares Outstanding	126.5M	126.5M	101.3M
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$168.8M	$175.2M	$136.4M
YoY Change	27.82%	28.44%	243.57%
Cash & Equivalents	$19.28M	$27.03M	$136.4M
Short-Term Investments	$149.5M	$148.1M
Other Short-Term Assets	$6.520M	$8.432M	$3.904M
YoY Change	158.01%	115.98%	100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$175.3M	$183.6M	$140.3M
YoY Change	30.27%	30.88%	236.84%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.204M	$1.373M	$2.142M
YoY Change	-34.92%	-35.9%	-64.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$320.0K	$320.0K	$320.0K
YoY Change	0.0%	0.0%	-32.06%
Total Long-Term Assets	$3.909M	$4.373M	$6.281M
YoY Change	-31.55%	-30.38%	-4.12%
TOTAL ASSETS
Total Short-Term Assets	$175.3M	$183.6M	$140.3M
Total Long-Term Assets	$3.909M	$4.373M	$6.281M
Total Assets	$179.2M	$188.0M	$146.6M
YoY Change	27.75%	28.25%	204.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$724.0K	$1.125M	$257.0K
YoY Change	-88.92%	337.74%	-75.78%
Accrued Expenses	$7.827M	$8.943M	$8.050M
YoY Change	137.11%	11.09%	524.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$9.698M	$11.19M	$9.334M
YoY Change	-10.9%	19.88%	-13.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.197M	$1.520M	$2.740M
YoY Change	-51.02%	-44.53%	-29.33%
Total Long-Term Liabilities	$1.197M	$1.520M	$2.740M
YoY Change	-51.02%	-44.53%	-29.33%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.698M	$11.19M	$9.334M
Total Long-Term Liabilities	$1.197M	$1.520M	$2.740M
Total Liabilities	$10.90M	$12.71M	$12.07M
YoY Change	-18.25%	5.27%	-18.01%
SHAREHOLDERS EQUITY
Retained Earnings	-$291.9M	-$280.7M	-$240.8M
YoY Change	17.13%	16.57%
Common Stock	$460.7M	$456.1M	$375.2M
YoY Change	22.31%	21.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$168.3M	$175.3M	$134.5M
YoY Change
Total Liabilities & Shareholders Equity	$179.2M	$188.0M	$146.6M
YoY Change	27.75%	28.25%	204.09%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$11.28M	-$7.837M	-$7.162M
YoY Change	32.78%	9.42%	-3.5%
Depreciation, Depletion And Amortization	$180.0K	$200.0K	$200.0K
YoY Change	-18.18%	0.0%	0.0%
Cash From Operating Activities	-$10.11M	-$12.23M	-$7.942M
YoY Change	119.85%	53.98%	41.69%
INVESTING ACTIVITIES
Capital Expenditures	$11.00K	$0.00	$194.0K
YoY Change	-82.54%	-100.0%	51.56%
Acquisitions
YoY Change
Other Investing Activities	-$656.0K	$4.269M	$1.000K
YoY Change	-99.38%	426800.0%	-99.13%
Cash From Investing Activities	-$667.0K	$4.269M	-$193.0K
YoY Change	-99.37%	-2311.92%	1384.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.031M	$41.00K	0.000
YoY Change			-100.0%
NET CHANGE
Cash From Operating Activities	-10.11M	-$12.23M	-7.942M
Cash From Investing Activities	-667.0K	$4.269M	-193.0K
Cash From Financing Activities	3.031M	$41.00K	0.000
Net Change In Cash	-7.749M	-$7.919M	-8.135M
YoY Change	-92.96%	-2.66%	8.57%
FREE CASH FLOW
Cash From Operating Activities	-$10.11M	-$12.23M	-$7.942M
Capital Expenditures	$11.00K	$0.00	$194.0K
Free Cash Flow	-$10.12M	-$12.23M	-$8.136M
YoY Change	117.11%	50.31%	41.92%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-270000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12229000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7942000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	-0	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	194000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	54919000	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	-0	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	59188000	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4269000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-193000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	41000	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	41000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7919000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8135000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	34946000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	144514000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27027000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	136379000	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-156000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	57000	usd
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	409000000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	175000000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5568000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1373000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1567000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	126507473
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27027000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34946000	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	148143000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	151663000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8432000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8182000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	183602000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	194791000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1373000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1567000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2680000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2967000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	320000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	320000	usd
CY2023Q1	us-gaap	Assets Assets	187975000	usd
CY2022Q4	us-gaap	Assets Assets	199645000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1125000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3382000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8943000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11690000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1122000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1097000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11190000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16169000	usd
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126507000
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	126495000
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126375000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	126302000
CY2022Q1	us-gaap	Depreciation Depreciation	200000	usd
CY2022Q4	cmpx	Number Of Operating Leases NumberOfOperatingLeases	1	pure
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y5M1D
CY2022Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y2M1D
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39696
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-4876496
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	80 Guest St., Suite 601
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02135
CY2023Q1	dei	City Area Code CityAreaCode	617
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	500-8099
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2023Q1	dei	Trading Symbol TradingSymbol	CMPX
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1520000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1838000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	12710000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	18007000	usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	13000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	456049000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	454741000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-146000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-302000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-280651000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-272814000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	175265000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	181638000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	187975000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	199645000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6638000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	4415000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3073000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2767000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	9711000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	7182000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9711000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7182000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1874000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	20000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7837000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7162000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7837000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.06
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	126375000
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100858000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7837000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	156000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7681000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7162000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	181638000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1267000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	41000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	156000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7837000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	175265000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	140078000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1574000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	134490000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-7837000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-7162000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	194000	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	165000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1267000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1574000	usd
CY2023Q1	cmpx	Marketable Securities Amortization Of Premium And Discount MarketableSecuritiesAmortizationOfPremiumAndDiscount	-593000	usd
CY2022Q1	cmpx	Marketable Securities Amortization Of Premium And Discount MarketableSecuritiesAmortizationOfPremiumAndDiscount	0	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	287000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	270000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	250000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1313000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2257000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-611000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2747000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-595000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-293000	usd
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	148289000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	116000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	262000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	148143000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	151965000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	64000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	366000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	151663000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	116781000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	134620000	usd
CY2023Q1	cmpx	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo	31362000	usd
CY2022Q4	cmpx	Debt Securities Availableforsale Fair Value Maturity Allocated And Single Maturity Date After Year One Through Two DebtSecuritiesAvailableforsaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughTwo	17043000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	148143000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	151663000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7135000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7135000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5762000	usd
CY2023Q1	cmpx	Accrued Project Expenses Current AccruedProjectExpensesCurrent	8280000	usd
CY2022Q4	cmpx	Accrued Project Expenses Current AccruedProjectExpensesCurrent	10038000	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	526000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1556000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	137000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	96000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8943000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11690000	usd
CY2023Q1	cmpx	Accrued Manufacturing Expenses AccruedManufacturingExpenses	8100000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.0625	pure
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	897000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1379000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	543000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2819000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	177000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	2642000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1122000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1520000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1267000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1574000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	18200000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5378000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.89
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y2M26D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	6316000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2238000
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.92
CY2023Q1	cmpx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Grants In Period Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm	P9Y9M
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12000
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.43
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	227000
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.76
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7377000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.88
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M8D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1953000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2854000
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.45
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y10M13D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	494000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.95
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	500000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.77
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0380	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0185	pure
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.89	pure
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.94	pure
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1900000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	20000	usd

Files In Submission

Name	View Source	Status
0001171843-23-002868-index-headers.html	Edgar Link	pending
0001171843-23-002868-index.html	Edgar Link	pending
0001171843-23-002868.txt	Edgar Link	pending
0001171843-23-002868-xbrl.zip	Edgar Link	pending
cmpx-20230331.xsd	Edgar Link	pending
cmpx20230331_10q.htm	Edgar Link	pending
ex_506857.htm	Edgar Link	pending
ex_506858.htm	Edgar Link	pending
ex_506859.htm	Edgar Link	pending
ex_506860.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
cmpx-20230331_cal.xml	Edgar Link	unprocessable
cmpx-20230331_lab.xml	Edgar Link	unprocessable
cmpx-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cmpx-20230331_def.xml	Edgar Link	unprocessable
cmpx20230331_10q_htm.xml	Edgar Link	completed
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CMPX
Compass Therapeutics Inc. Stock $cmpx

2023 Q2 Form 10-Q Financial Statement

#000117184323002868 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMPX Compass Therapeutics Inc. Stock $cmpx

2023 Q2 Form 10-Q Financial Statement

#000117184323002868 Filed on May 04, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CMPX
Compass Therapeutics Inc. Stock $cmpx